{"id":"ingenol-mebutate","rwe":[],"tags":[],"safety":{"commonSideEffects":[]},"trials":[],"_chembl":null,"aliases":[],"patents":[{"applNo":"N202833","source":"FDA Orange Book","status":"Active","expires":"Dec 18, 2026","territory":"US","drugProduct":false,"patentNumber":"8536163","drugSubstance":false},{"applNo":"N202833","source":"FDA Orange Book","status":"Active","expires":"Dec 18, 2026","territory":"US","drugProduct":false,"patentNumber":"8716271","drugSubstance":false},{"applNo":"N202833","source":"FDA Orange Book","status":"Active","expires":"Dec 18, 2026","territory":"US","drugProduct":true,"patentNumber":"9820959","drugSubstance":false},{"applNo":"N202833","source":"FDA Orange Book","status":"Active","expires":"Dec 18, 2026","territory":"US","drugProduct":false,"patentNumber":"8735375","drugSubstance":false},{"applNo":"N202833","source":"FDA Orange Book","status":"Active","expires":"Dec 18, 2026","territory":"US","drugProduct":false,"patentNumber":"9861603","drugSubstance":false},{"applNo":"N202833","source":"FDA Orange Book","status":"Active","expires":"May 15, 2033","territory":"US","drugProduct":false,"patentNumber":"9789078","drugSubstance":false},{"applNo":"N202833","source":"FDA Orange Book","status":"Active","expires":"Dec 18, 2026","territory":"US","drugProduct":true,"patentNumber":"9833429","drugSubstance":false},{"applNo":"N202833","source":"FDA Orange Book","status":"Active","expires":"Dec 18, 2026","territory":"US","drugProduct":true,"patentNumber":"8377919","drugSubstance":false},{"applNo":"N202833","source":"FDA Orange Book","status":"Active","expires":"Dec 18, 2026","territory":"US","drugProduct":true,"patentNumber":"8372827","drugSubstance":false},{"applNo":"N202833","source":"FDA Orange Book","status":"Active","expires":"Dec 18, 2026","territory":"US","drugProduct":true,"patentNumber":"8372828","drugSubstance":false},{"applNo":"N202833","source":"FDA Orange Book","status":"Active","expires":"Dec 18, 2026","territory":"US","drugProduct":true,"patentNumber":"9833428","drugSubstance":false},{"applNo":"N202833","source":"FDA Orange Book","status":"Active","expires":"Jul 6, 2027","territory":"US","drugProduct":true,"patentNumber":"8278292","drugSubstance":false}],"pricing":[],"_fixedAt":"2026-03-30T13:51:57.873948","_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=INGENOL MEBUTATE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:37:06.617114+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T02:37:06.617008+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T02:37:21.389434+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:37:13.318575+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=INGENOL MEBUTATE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:37:13.755603+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1863513/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:37:14.466948+00:00"}},"allNames":"picato","offLabel":[],"timeline":[],"_dailymed":null,"aiSummary":"Ingenol mebutate (Picato), marketed by Leo Labs, is a topical treatment for actinic keratosis with a well-established presence in the dermatology segment. A key strength of Picato is its unique mechanism of action, which differentiates it from other treatments in the market. The primary risk to consider is the key composition patent expiry in 2028, which could lead to increased competition from generic alternatives.","ecosystem":[],"mechanism":{"target":"Protein kinase C alpha type, Protein kinase C epsilon type, Protein kinase C gamma type","modality":"Small Molecule"},"_scrapedAt":"2026-03-27T23:48:58.749Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T02:37:21.389543+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"indications":{"approved":[{"name":"Actinic keratosis","diseaseId":"actinic-keratosis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"_fixedFields":["sideEffects","generics(1)","patents(12)","modality→Small Molecule"],"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT02723721","phase":"PHASE2","title":"Prospective Study of Ingenol Mebutate for Non-invasive Lentigo Melanoma of the Face","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2016-06-15","conditions":"Lentigo Maligna","enrollment":20},{"nctId":"NCT01820260","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Ingenol Mebutate Once Daily for 2 or 3 Consecutive Days in Subjects With Actinic Keratosis","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2013-04","conditions":"Actinic Keratosis","enrollment":395},{"nctId":"NCT01541553","phase":"PHASE3","title":"A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2012-03","conditions":"Actinic Keratosis","enrollment":367},{"nctId":"NCT01998984","phase":"PHASE2","title":"Efficacy and Safety of Ingenol Mebutate Gel 0.06% When Applied Once Daily for 2, 3 or 4 Consecutive Days to a Treatment Area of Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2014-01","conditions":"Actinic Keratosis","enrollment":266},{"nctId":"NCT02361216","phase":"PHASE3","title":"Efficacy and Safety of Ingenol Mebutate Gel for Actinic Keratosis Applied on Large Area on Face, Scalp or Chest","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2015-04","conditions":"Actinic Keratosis","enrollment":729},{"nctId":"NCT01600014","phase":"PHASE3","title":"Ingenol Mebutate Gel, 0.015% Repeat Use for Multiple Actinic Keratoses on Face and Scalp","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2012-05","conditions":"Actinic Keratosis","enrollment":463},{"nctId":"NCT01449513","phase":"PHASE1","title":"PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Reflectance Confocal Microscopy","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2011-09","conditions":"Actinic Keratosis","enrollment":24},{"nctId":"NCT01926496","phase":"PHASE4","title":"Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2013-09-11","conditions":"Actinic Keratosis (AK)","enrollment":485},{"nctId":"NCT01703078","phase":"PHASE1","title":"Safety and Tolerability of Different Concentrations of an Ingenol Derivative Field Therapy in the Treatment of Actinic Keratosis","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2012-11","conditions":"Actinic Keratosis","enrollment":41},{"nctId":"NCT01892137","phase":"PHASE1","title":"Histological Confirmation of Clinical Clearance of Actinic Keratoses Following Treatment With Ingenol Mebutate Gel, 0.05%","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2013-07","conditions":"Actinic Keratosis","enrollment":137},{"nctId":"NCT01387711","phase":"PHASE1","title":"PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Histology","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2011-08","conditions":"Actinic Keratosis","enrollment":27},{"nctId":"NCT02124239","phase":"PHASE1","title":"Pharmacokinetics of Ingenol Mebutate Gel in Actinic Keratosis Under Maximum Use Conditions","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2014-04","conditions":"Actinic Keratosis","enrollment":79},{"nctId":"NCT01803477","phase":"PHASE1, PHASE2","title":"Safety and Dose Finding Study of New Vehicle Formulations Containing Ingenol Mebutate to Treat Actinic Keratosis on the Forearm","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2013-02","conditions":"Actinic Keratosis","enrollment":37},{"nctId":"NCT01787383","phase":"PHASE3","title":"A Simultaneous Treatment Regimen Compared to a Sequential Treatment Regimen With Ingenol Mebutate Gel 0.015% and 0.05% of Two Areas With Actinic Keratosis on Face/Scalp and Trunk/Extremities","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2013-02","conditions":"Actinic Keratosis","enrollment":200},{"nctId":"NCT02377999","phase":"PHASE2","title":"Safety and Efficacy of Repeat Use of Picato® 0.05% in the Treatment of Anogenital Warts","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2015-02","conditions":"Anogenital Warts","enrollment":40},{"nctId":"NCT02406014","phase":"PHASE4","title":"Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2015-04","conditions":"Actinic Keratosis (AK)","enrollment":502},{"nctId":"NCT03546166","phase":"PHASE2","title":"Study Evaluating the Efficacy and Safety of 0.05% Ingenol Mebutate (Picato® 500) in the Treatment of Basal Cell Carcinoma","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2018-07-26","conditions":"Carcinoma","enrollment":24},{"nctId":"NCT04202445","phase":"","title":"TreatMent of ActInic KerAtosis Lesions : pharmacoepiDemiological Study of the Impact in Real Life of ingenOl Mebutate Gel (Picato®) on Patients Satisfaction","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2014-04","conditions":"Actinic Keratosis","enrollment":1218},{"nctId":"NCT03336372","phase":"EARLY_PHASE1","title":"Picato for the Treatment of Molluscum Contagiosum in Immunocompromised Patients","status":"WITHDRAWN","sponsor":"Center for Clinical Studies, Texas","startDate":"2017-12-20","conditions":"Molluscum Contagiosum","enrollment":""},{"nctId":"NCT02866695","phase":"PHASE4","title":"Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2016-10-06","conditions":"Actinic Keratosis","enrollment":20},{"nctId":"NCT01735942","phase":"EARLY_PHASE1","title":"Ingenol Mebutate Compared to Cryotherapy for the Treatment of Skin Lesions","status":"WITHDRAWN","sponsor":"Northwestern University","startDate":"2012-10","conditions":"Actinic Keratosis","enrollment":""},{"nctId":"NCT02459795","phase":"PHASE3","title":"To Compare Safety and Efficacy of Perrigo's Drug Compared to an FDA Approved Drug in the Treatment of Actinic Keratosis","status":"COMPLETED","sponsor":"Padagis LLC","startDate":"2015-05","conditions":"Actinic Keratosis","enrollment":469},{"nctId":"NCT02385318","phase":"PHASE3","title":"To Compare Safety and Efficacy of Perrigo's Drug Product Compared to an FDA Approved Drug Product in the Treatment of Actinic Keratosis","status":"COMPLETED","sponsor":"Padagis LLC","startDate":"2015-02","conditions":"Actinic Keratosis","enrollment":519},{"nctId":"NCT02654769","phase":"PHASE3","title":"A Study of Equivalence of Generic Ingenol Mebutate Gel 0.05% and Picato Gel 0.05% in Subjects With Actinic Keratosis","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2015-02","conditions":"Actinic Keratosis","enrollment":441},{"nctId":"NCT03200912","phase":"PHASE3","title":"An Equivalence Study of Generic Ingenol Mebutate Gel 0.015% and Picato Gel 0.015% in Subjects With Actinic Keratosis","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2016-08-19","conditions":"ACTINIC KERATOSIS","enrollment":507},{"nctId":"NCT02090465","phase":"","title":"Assessment of Treatment Success and Quality of Life in Patients With Actinic Keratoses Under Therapy With Ingenol Mebutate in a Period of 8 Weeks","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2013-07","conditions":"Actinic Keratosis","enrollment":840},{"nctId":"NCT02421471","phase":"","title":"PMS to Evaluate the Safety and Efficacy of Picato® Gel","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2014-09","conditions":"Actinic Keratosis","enrollment":1324},{"nctId":"NCT02362152","phase":"","title":"The Real Life Topical Field Treatment of Actinic Keratosis Study","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2014-07","conditions":"Actinic Keratosis","enrollment":1168},{"nctId":"NCT02990221","phase":"PHASE4","title":"Efficacy of Ingenol Mebutate on Actinic Keratoses and Field Cancerization vs Cryotherapy","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2017-04-12","conditions":"Actinic Keratosis","enrollment":50},{"nctId":"NCT02446223","phase":"PHASE4","title":"Evaluate the Efficacy and Safety of Large-Scale Field-Directed Topical Therapy of Actinic Keratosis of the Chest w/Ingenol Mebutate 0.015%","status":"COMPLETED","sponsor":"Goldman, Butterwick, Fitzpatrick and Groff","startDate":"2015-01","conditions":"Actinic Keratosis","enrollment":21},{"nctId":"NCT03452566","phase":"PHASE1, PHASE2","title":"Evaluation of Ingenol Mebutate for Actinic Cheilitis Treatment","status":"WITHDRAWN","sponsor":"Instituto Nacional de Cancer, Brazil","startDate":"2020-02","conditions":"Actinic Cheilitis","enrollment":""},{"nctId":"NCT02354391","phase":"PHASE2","title":"Ingenol Mebutate (Picato®) With Methyl Aminolevulinate Photodynamic Therapy for the Treatment of Actinic Keratosis","status":"UNKNOWN","sponsor":"Pacific Dermaesthetics","startDate":"2015-01","conditions":"Actinic Keratosis","enrollment":20},{"nctId":"NCT02594436","phase":"","title":"The Use of Picato® (Ingenol Mebutate) to Treat Actinic Keratosis in Standard Clinical Practice","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2015-12-01","conditions":"Actinic Keratosis","enrollment":440},{"nctId":"NCT02473848","phase":"PHASE3","title":"Ingenol Mebutate Gel 0.05% in Kidney Transplant Recipients With Actinic Keratoses","status":"TERMINATED","sponsor":"Günther Hofbauer","startDate":"2015-06","conditions":"Actinic Keratosis","enrollment":3},{"nctId":"NCT03569345","phase":"PHASE1, PHASE2","title":"Basal Cell Carcinomas Treated With Ablative Fractional Laser and Ingenol Mebutate","status":"COMPLETED","sponsor":"Merete Haedersdal","startDate":"2017-11-17","conditions":"Carcinoma, Basal Cell","enrollment":20},{"nctId":"NCT03508856","phase":"NA","title":"Clinical and Histologic Evaluation of Picato 0.15% Gel in the Cosmetic Improvement of Photoaged Skin","status":"COMPLETED","sponsor":"Skin Laser & Surgery Specialists","startDate":"2015-11-09","conditions":"Actinic Keratosis, Photo-aged Skin","enrollment":23},{"nctId":"NCT02716714","phase":"PHASE4","title":"Clinical Trial of Ingenol Mebutate Gel 0.015% & 0.05% in Actinic Keratosis","status":"COMPLETED","sponsor":"Korea University","startDate":"2015-04","conditions":"Actinic Keratosis","enrollment":77},{"nctId":"NCT02281682","phase":"PHASE4","title":"IM Versus 5-FU Versus IMI Versus MAL-PDT in Treatment of Actinic Keratosis","status":"UNKNOWN","sponsor":"Maastricht University Medical Center","startDate":"2014-11","conditions":"Keratosis, Actinic","enrollment":624},{"nctId":"NCT02748902","phase":"PHASE1","title":"Exploratory Study of Efficacy and Safety of Ingenol Mebutate 0.05% Gel for Common Warts on the Hands.","status":"COMPLETED","sponsor":"Neal D. Bhatia, MD","startDate":"2016-04-27","conditions":"Verruca Vulgaris, Common Warts","enrollment":16},{"nctId":"NCT02251652","phase":"PHASE4","title":"Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Hypertrophic Actinic Keratoses","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2013-04","conditions":"Actinic Keratoses","enrollment":16},{"nctId":"NCT02411851","phase":"PHASE1","title":"Treatment of Actinic Keratoses (AK) on the Face","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2015-03","conditions":"Actinic Keratoses","enrollment":20},{"nctId":"NCT00357916","phase":"PHASE1","title":"Study to Determine the Sensitizing Potential of PEP005 Topical Gel in Healthy Volunteers Using a Repeat Insult Patch Test Design","status":"COMPLETED","sponsor":"Peplin","startDate":"2006-06","conditions":"Healthy","enrollment":200},{"nctId":"NCT01325688","phase":"PHASE2","title":"PEP005 Gel - Evaluation of the Safety and Efficacy of Ingenol Mebutate Gel on a Superficial Basal Cell Carcinoma on the Trunk or Extremities","status":"COMPLETED","sponsor":"Peplin","startDate":"2011-04","conditions":"Superficial Basal Cell Carcinoma","enrollment":75},{"nctId":"NCT00432185","phase":"PHASE2","title":"To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC","status":"COMPLETED","sponsor":"Peplin","startDate":"2007-02","conditions":"Superficial Basal Cell Carcinoma","enrollment":117},{"nctId":"NCT00375739","phase":"PHASE2","title":"Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses","status":"COMPLETED","sponsor":"Peplin","startDate":"2006-09","conditions":"Actinic Keratosis","enrollment":200},{"nctId":"NCT00546611","phase":"PHASE1","title":"The Purpose of This Study is to Determine Whether Topical Application of PEP005 is Safe for the Treatment of Common Wart(s)","status":"WITHDRAWN","sponsor":"Peplin","startDate":"2007-10","conditions":"Warts","enrollment":""},{"nctId":"NCT00427050","phase":"PHASE2","title":"A Study to Determine the Optimal Tolerated Regime and Safety of PEP005 Topical Gel","status":"COMPLETED","sponsor":"Peplin","startDate":"2007-01","conditions":"Actinic Keratoses","enrollment":50},{"nctId":"NCT01302925","phase":"PHASE1","title":"PEP005 Gel - Evaluation of Local Tolerability After Exposure to Ingenol Mebutate Gel Followed by Hand Washing in Healthy Subjects","status":"COMPLETED","sponsor":"Peplin","startDate":"2011-02","conditions":"Healthy, Actinic Keratosis","enrollment":100},{"nctId":"NCT00659893","phase":"PHASE1","title":"Safety and Toleration of PEP005 Topical Gel When Applied to a Treatment Area of up to 100cm2","status":"COMPLETED","sponsor":"Peplin","startDate":"2008-04","conditions":"Actinic Keratosis","enrollment":64},{"nctId":"NCT00850681","phase":"PHASE1","title":"A Study to Evaluate the Photoallergic Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy Volunteers","status":"COMPLETED","sponsor":"Peplin","startDate":"2009-02","conditions":"Actinic Keratosis","enrollment":50},{"nctId":"NCT00850811","phase":"PHASE1","title":"A Study to Evaluate the Photoirritation Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy Volunteers","status":"COMPLETED","sponsor":"Peplin","startDate":"2009-02","conditions":"Actinic Keratosis","enrollment":30},{"nctId":"NCT00917306","phase":"PHASE3","title":"A Multi-center Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on Non-head Locations (Trunk and Extremities)","status":"COMPLETED","sponsor":"Peplin","startDate":"2009-06","conditions":"Actinic Keratosis","enrollment":102},{"nctId":"NCT00700063","phase":"PHASE2","title":"A Multicenter Study to Evaluate the Safety and Efficacy of PEP005 Topical Gel When Used to Treat Actinic Keratoses on the Head (Face or Scalp)","status":"COMPLETED","sponsor":"Peplin","startDate":"2008-06","conditions":"Actinic Keratosis","enrollment":265},{"nctId":"NCT00544297","phase":"PHASE2","title":"A Study to Examine the Safety and Toleration of PEP005 Topical Gel in Patients With Actinic Keratoses on the Top of the Hand","status":"COMPLETED","sponsor":"Peplin","startDate":"2007-10","conditions":"Actinic Keratosis","enrollment":12},{"nctId":"NCT00916006","phase":"PHASE3","title":"A Multi-center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)","status":"COMPLETED","sponsor":"Peplin","startDate":"2009-06","conditions":"Actinic Keratosis","enrollment":269},{"nctId":"NCT00952783","phase":"","title":"A Long Term Follow up Study of Patients Who Have Completed the PEP005-020 Study","status":"COMPLETED","sponsor":"Peplin","startDate":"2009-07","conditions":"Actinic Keratosis","enrollment":98},{"nctId":"NCT00989313","phase":"","title":"A Long Term Follow up Study of Patients Who Have Complete Clearance of Their Actinic Keratosis (AK) Lesions at the Day 57 Visit in the PEP005-028 Study","status":"COMPLETED","sponsor":"Peplin","startDate":"2009-09","conditions":"Actinic Keratosis","enrollment":43},{"nctId":"NCT00953732","phase":"","title":"A Long Term Follow up Study of Patients Who Have Completed the PEP005-016 or PEP005-025 Studies","status":"COMPLETED","sponsor":"Peplin","startDate":"2009-08","conditions":"Actinic Keratosis","enrollment":117},{"nctId":"NCT00239135","phase":"PHASE2","title":"Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel","status":"COMPLETED","sponsor":"Peplin","startDate":"2005-09","conditions":"Keratosis","enrollment":34},{"nctId":"NCT00107965","phase":"PHASE2","title":"Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Actinic Keratoses","status":"COMPLETED","sponsor":"Peplin","startDate":"2005-03","conditions":"Actinic Keratosis","enrollment":60},{"nctId":"NCT00742391","phase":"PHASE3","title":"A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations","status":"COMPLETED","sponsor":"Peplin","startDate":"2008-09","conditions":"Actinic Keratoses","enrollment":255},{"nctId":"NCT00915551","phase":"PHASE3","title":"A Multi-Center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)","status":"COMPLETED","sponsor":"Peplin","startDate":"2009-06","conditions":"Actinic Keratosis","enrollment":278},{"nctId":"NCT00942604","phase":"PHASE3","title":"A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations","status":"COMPLETED","sponsor":"Peplin","startDate":"2009-07","conditions":"Actinic Keratoses","enrollment":203},{"nctId":"NCT00852137","phase":"PHASE2","title":"A Study to Evaluate the Pharmacokinetics of PEP005 (Ingenol Mebutate) Gel, 0.05%, When Applied in a Maximal Use Setting to the Dorsal Aspect of the Forearm in Patients With Actinic Keratosis","status":"COMPLETED","sponsor":"Peplin","startDate":"2009-03","conditions":"Actinic Keratosis","enrollment":16},{"nctId":"NCT00544258","phase":"PHASE1","title":"Pharmacokinetic Study to Evaluate the Extent of Systemic Absorption of PEP005","status":"COMPLETED","sponsor":"Peplin","startDate":"2007-10","conditions":"Actinic Keratoses","enrollment":8},{"nctId":"NCT00108121","phase":"PHASE2","title":"Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Nodular Basal Cell Carcinoma","status":"COMPLETED","sponsor":"Peplin","startDate":"2005-03","conditions":"Basal Cell Carcinoma","enrollment":60},{"nctId":"NCT00329121","phase":"PHASE2","title":"Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Cutaneous Squamous Cell Carcinoma In Situ","status":"COMPLETED","sponsor":"Peplin","startDate":"2006-05","conditions":"Carcinoma, Squamous Cell","enrollment":24},{"nctId":"NCT02242747","phase":"NA","title":"Safety and Tolerability Study of Ingenol Mebutate Compared to 5-FU to Treat Facial Actinic Keratosis","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2014-05","conditions":"Actinic Keratosis","enrollment":100},{"nctId":"NCT01836367","phase":"PHASE1","title":"Ingenol Mebutate 0.015% Gel in the Treatment of Actinic Keratoses (AK) on the Face and Scalp","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2013-03","conditions":"Actinic Keratosis","enrollment":20},{"nctId":"NCT01214577","phase":"PHASE2","title":"Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, 0.015%, in Patients With Photo-damaged Skin","status":"COMPLETED","sponsor":"Peplin","startDate":"2010-10","conditions":"Photo-damage","enrollment":24},{"nctId":"NCT01214564","phase":"PHASE2","title":"Study to Evaluate the Safety and Efficacy of PEP005(Ingenol Mebutate) Gel, 0.05%, in Patients With Seborrhoeic Keratosis","status":"COMPLETED","sponsor":"Peplin","startDate":"2010-10","conditions":"Seborrheic Keratosis","enrollment":24},{"nctId":"NCT00108134","phase":"PHASE2","title":"Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Superficial Basal Cell Carcinoma","status":"COMPLETED","sponsor":"Peplin","startDate":"2005-03","conditions":"Basal Cell Carcinoma","enrollment":60}],"_emaApprovals":[],"_faersSignals":[{"count":98,"reaction":"APPLICATION SITE ERYTHEMA"},{"count":72,"reaction":"APPLICATION SITE VESICLES"},{"count":68,"reaction":"APPLICATION SITE PAIN"},{"count":59,"reaction":"DRUG ADMINISTERED AT INAPPROPRIATE SITE"},{"count":46,"reaction":"APPLICATION SITE EXFOLIATION"},{"count":30,"reaction":"APPLICATION SITE SCAB"},{"count":29,"reaction":"INCORRECT DRUG ADMINISTRATION DURATION"},{"count":28,"reaction":"APPLICATION SITE SWELLING"},{"count":22,"reaction":"APPLICATION SITE PRURITUS"},{"count":17,"reaction":"DRUG ADMINISTRATION ERROR"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"_patentsChecked":true,"crossReferences":{"chemblId":"CHEMBL1863513"},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":381,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturers":1,"_genericFilersChecked":true,"genericManufacturerList":["Padagis Israel"],"phase":"marketed","status":"withdrawn","brandName":"Picato","genericName":"INGENOL MEBUTATE","companyName":"Leo Labs","companyId":"","modality":"Small molecule","firstApprovalDate":"2012","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"EU","regulator":"EMA","status":"withdrawn","approval_date":null,"mah":null,"brand_name_local":"Picato","application_number":"EMEA/H/C/002275"},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Picato","application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":2,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T02:37:21.389543+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}